Kodiak Sciences (KOD)

Executive Summary

Kodiak Sciences is a clinical-stage biopharmaceutical company leveraging its proprietary Antibody Biopolymer Conjugate (ABC) platform to develop next-generation therapies for retinal diseases that cause blindness. Despite setbacks with its earlier KSI-301 program (multiple Phase 3 trials terminated due to efficacy or safety concerns), the company has pivoted to new candidates. Its lead pipeline now includes tarcocimab (a novel anti-VEGF agent) in a Phase 3 trial for diabetic retinopathy, which completed enrollment in January 2026, and KSI-101 (an anti-inflammatory ABC) in a Phase 3 trial for macular edema secondary to inflammation, currently recruiting. The company also has a Phase 3 combo trial (tarcocimab + tabirafusp + aflibercept) for wet AMD. While Kodiak's history of clinical failures raises caution, its ABC platform offers potential for durable, less frequent dosing—a key unmet need in retinal care. Upcoming data readouts and pipeline progress will be critical for determining its commercial viability.

Upcoming Catalysts (preview)

• Q2 2026Topline data from tarcocimab Phase 3 trial in diabetic retinopathy (NCT06270836)60% success
• H2 2026Enrollment completion or interim analysis for KSI-101 Phase 3 in macular edema secondary to inflammation (NCT06990399)70% success
• TBDPotential strategic partnership for ABC platform or pipeline assets50% success